GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome.
Overview
- Semel Institute for Neuroscience and Human Behavior, Intellectual and Developmental Disability Center (IDDRC), Brain Injury Research Center (BIRC), David Geffen School of Medicine, UCLA, 635 Charles E. Young Drive South, NRB315, Los Angeles, CA 90095 USA
- Department of Chemistry and Biochemistry, Molecular Biology Institute, David Geffen School of Medicine, UCLA, Los Angeles, CA USA
- Molecular Instrumentation Center (MIC), Department of Chemistry and Biochemistry, UCLA, Los Angeles, CA USA
- Department of Anesthesiology, Neurosurgery and Neuroscience, University of Florida, Gainesville, FL 32610-0254 USA
- Department of Radiological Sciences, Geffen School of Medicine, UCLA, Los Angeles, CA USA
- Department of Computational Medicine, Statistics Core of the Department of Medicine, School of Public Health, UCLA, Los Angeles, CA USA
- BRAINBox Solutions, Inc., Richmond, VA 23219 USA
- Department of Neuroscience, University of Florida College of Medicine, Gainesville, FL 32610 USA
- EnCor Biotechnology Inc., Gainesville, FL 32608 USA
- Department Neurology and Neurosurgery, BIRC, David Geffen School of Medicine, Ronald Reagan Medical Center, UCLA, Los Angeles, CA USA
Abstract
Glial fibrillary acidic protein (GFAP) is a significant clinical biomarker of traumatic brain injury (TBI), yet understanding the nature, timing, and impact of its degraded and modified products would inform clinical utility. We report novel GFAP breakdown products (BDPs) and post-translational modifications (PTMs) that are unique to TBI including fragment- and patient-specific citrullination signatures that destabilize GFAP filaments. GFAP and its fragments were sequenced by mass spectrometry (MS) from severe TBI patients’ cerebrospinal fluid (CSF) and sera, identifying two distinct TBI-specific jointly generated product sets within the rod-domain covering coil1 (20–26 kDa) and coil2 (15–19 kDa). Their endings differed from GFAP fragments described in Alzheimer’s and Alexander disease. Label-free quantification showed biofluid co-product abundance differences with coil1-BDPs enriched over coil2-BDPs. Coil imbalance was independently confirmed by immunoblot densitometry in twenty-three TBI patients. Measurements over ten days showed injury day peaks of full-length and end-clipped GFAP fragments, while proteolytic 37/
Supplementary Information: The online version contains supplementary material available at 10.1186/
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
The paper's code and data availability statement is in the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- uniprot.org/
uniprotkb/ , at UniProt; found in the text, “Immunoprecipitation and mass spectrometry…”p14136
Data availability
Dataset for longitudinal CSF quantification of GFAP and its fragments is available in Open Data Commons TBI: https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 30 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 15 authors, 8 keywords, 13 MeSH terms, 7 funders, 108 references, 1 RRID.
Cite
This paper
Wanner, I.-B., Halford, J., Lopez, J., Shen, S., Chen, Y., Zhao, H., Salas, C., Loo, R. O., Robicsek, S., Ellingson, B. M., Gornbein, J., Van Meter, T. E., Shaw, G., Loo, J. A., & Vespa, P. M. (2026). GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome. Acta neuropathologica communications, 14(1), 101. https://
BibTeX
@article{wanner2026gfap,
author = {Wanner, Ina-Beate and Halford, Julia and Lopez, Jonathan and Shen, Sean and Chen, Yu and Zhao, Hayden and Salas, Carolina and Loo, Rachel Ogorzalek and Robicsek, Steven and Ellingson, Benjamin M and Gornbein, Jeffrey and Van Meter, Timothy E and Shaw, Gerry and Loo, Joseph A and Vespa, Paul M},
title = {{GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome}},
journal = {Acta neuropathologica communications},
year = {2026},
month = apr,
volume = {14},
number = {1},
pages = {101},
publisher = {BMC},
issn = {2051-5960},
doi = {10.1186/
url = {https://
pmid = {42032706},
pmcid = {PMC13107622}
}
RIS
TY - JOUR
AU - Wanner, Ina-Beate
AU - Halford, Julia
AU - Lopez, Jonathan
AU - Shen, Sean
AU - Chen, Yu
AU - Zhao, Hayden
AU - Salas, Carolina
AU - Loo, Rachel Ogorzalek
AU - Robicsek, Steven
AU - Ellingson, Benjamin M
AU - Gornbein, Jeffrey
AU - Van Meter, Timothy E
AU - Shaw, Gerry
AU - Loo, Joseph A
AU - Vespa, Paul M
TI - GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome
T2 - Acta neuropathologica communications
J2 - Acta Neuropathol Commun
PY - 2026
DA - 2026/
VL - 14
IS - 1
SP - 101
SN - 2051-5960
PB - BMC
DO - 10.1186/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1186/
"type": "article-journal",
"title": "GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome",
"container-title": "Acta neuropathologica communications",
"author": [
{
"family": "Wanner",
"given": "Ina-Beate"
},
{
"family": "Halford",
"given": "Julia"
},
{
"family": "Lopez",
"given": "Jonathan"
},
{
"family": "Shen",
"given": "Sean"
},
{
"family": "Chen",
"given": "Yu"
},
{
"family": "Zhao",
"given": "Hayden"
},
{
"family": "Salas",
"given": "Carolina"
},
{
"family": "Loo",
"given": "Rachel Ogorzalek"
},
{
"family": "Robicsek",
"given": "Steven"
},
{
"family": "Ellingson",
"given": "Benjamin M"
},
{
"family": "Gornbein",
"given": "Jeffrey"
},
{
"family": "Van Meter",
"given": "Timothy E"
},
{
"family": "Shaw",
"given": "Gerry"
},
{
"family": "Loo",
"given": "Joseph A"
},
{
"family": "Vespa",
"given": "Paul M"
}
],
"container-title-short":
"volume": "14",
"issue": "1",
"page": "101",
"DOI": "10.1186/
"PMID": "42032706",
"PMCID": "PMC13107622",
"ISSN": "2051-5960",
"publisher": "BMC",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
24
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.4103/nrr.nrr-d-25-00902
- Mild and repetitive mild traumatic brain injury: Changes in microglial cells and synapses.Journal: Neural regeneration researchIn common: traumatic brain injury, 7 references
- [2] doi:10.1016/j.ebiom.2025.106001 [code]
- Beyond mild, moderate, and severe traumatic brain injury: modelling severity from clinical, neuroimaging, and blood-based indicators.Journal: EBioMedicineIn common: traumatic brain injury, 5 references
- [3] doi:10.3390/bioengineering9110612
- Traumatic Brain Injury Biomarkers, Simulations and Kinetics.Journal: Bioengineering (Basel, Switzerland)In common: traumatic brain injury, other, 4 references
- [4] doi:10.1016/j.redox.2026.104103
- Alexander disease mutations differentially sensitize glial fibrillary acidic protein (GFAP) to posttranslational modifications and network disruption by oxidants.Journal: Redox biologyIn common: other, 4 references
- [5] doi:10.1093/braincomms/fcag055 [code]
- Serum biomarker trajectory clusters predict functional outcome and quality of life for traumatic brain injury.Journal: Brain communicationsIn common: traumatic brain injury, other, 4 references
- [6] doi:10.3390/biomedicines13112669
- A Bioinformatic Study of Genetics Involved in Determining Mild Traumatic Brain Injury Severity and Recovery.Journal: BiomedicinesIn common: traumatic brain injury, 4 references
- [7] doi:10.1177/08977151251362101
- Effects of Lifetime Exposure to Sports-Related Head Impacts on Brain Injury and Inflammatory Blood Biomarkers Among Former Middle-Aged Athletes.Journal: Neurotrauma reportsIn common: traumatic brain injury, other, 3 references
- [8] doi:10.1177/2689288x261446294
- Proteomic Changes of Neurodegenerative and Inflammatory Plasma Biomarkers Following Traumatic Brain Injury.Journal: Neurotrauma reportsIn common: traumatic brain injury, other, 3 references
- [9] doi:10.1038/s41598-026-53148-5
- Neurovascular and inflammatory effects of biperiden in the acute phase of moderate traumatic brain injury: evidence from a non-human primate model.Journal: Scientific reportsIn common: traumatic brain injury, other, 3 references
- [10] doi:10.1002/glia.70049 [code]
- Mutations in GFAP Alter Early Lineage Commitment of Organoids.Journal: GliaIn common: other, 3 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
